Friday, April 10, 2026 – (MedPage Today) — GLP-1 receptor agonist use may be associated with a modest increase in erectile dysfunction (ED) risk in men with type 2 diabetes, a target trial emulation suggested.
Using U.S. electronic health record data, the incidence of…

Friday, April 10, 2026 – Here’s everything we know so far.

Friday, April 10, 2026 – New China-US biotech gets $54M: Vivatides Therapeutics raised the Series A for its preclinical-stage R&D in siRNA and antisense oligonucleotides aimed at reaching tissues beyond the liver. Vivatides’ investors include …

Friday, April 10, 2026 – Friday, April 10 – By using AI to analyze more than 400,000 Reddit posts, Penn researchers have identified patient-reported symptoms associated with GLP-1s, the popular weight-loss and diabetes drugs semaglutide and tirzepatide, that may not be fully captured in clinical trials or regulatory documents.

Friday, April 10, 2026 – Friday, April 10 – → A decorated GLP-1 pioneer is retiring at Novo Nordisk.

Channeling Elvis Presley with a microphone emoji for good measure, Lotte Bjerre Knudsen said on LinkedIn that she “has left the …

Friday, April 10, 2026 – Friday, April 10 – Research suggests GLP-1 drugs like Ozempic and Wegovy could double divorce risk, mirroring trends seen in bariatric surgery patients, experts say.

Thursday, April 9, 2026 – Friday, April 10 – Adults with overweight or obesity taking the new generation of weight loss drugs semaglutide and tirzepatide tend to eat significantly less, leaving them vulnerable to nutritional deficiencies, according to one of the first real-world studies to examine dietary behavior in people using glucagon-like peptide-1 receptor agonists and dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) dual agonists RAs (collectively referred to as GLP-1 RAs) with the help of an AI-powered nutritional tracking app.

Thursday, April 9, 2026 – Friday, April 10 – (MedPage Today) — Integrating the most effective obesity treatments into cancer survivorship offers “an unprecedented opportunity” to improve long-term outcomes in cancer, including survival, a trio of obesity and oncology specialists argued in…

Thursday, April 9, 2026 – Friday, April 10 – The traditional biotech venture model under pressure, PhRMA chief Ubl to exit, and other biotech news from The Readout

Thursday, April 9, 2026 – Friday, April 10 – Steve Ubl, chief executive of PhRMA, plans to step down at the end of the ‌year, after more than a decade leading the main trade group for brand-name drug makers

Wednesday, April 8, 2026 – Thursday, April 9 – 23andMe Research Institute, a nonprofit medical research organization, announced the publication of a study that identifies genetic predictors for GLP-1 weight loss efficacy and side effects. GLP-1 receptor agonists, including semaglutide and tirzepatide, have transformed the clinical management of weight and obesity. However, patients experience substantial variability in both weight loss efficacy and the incidence of side effects. Some individuals lose less than 5% of their body weight, whereas others lose more than 20%. Some individuals experience side effects such as nausea and vomiting, whereas others do not.

Wednesday, April 8, 2026 – Thursday, April 9 – Changes in two genes appear to help predict whether patients will lose substantial weight on GLP-1 drugs — and whether the drugs will cause nausea or vomiting.

Wednesday, April 8, 2026 – Thursday, April 9 –

Tuesday, April 7, 2026 – Wednesday April 8 – (MedPage Today) — In a whistleblower lawsuit, a prominent cardiologist says he was fired from the University of Pittsburgh Medical Center (UPMC) after reporting racist text messages exchanged between colleagues and a potential conflict of interest…

Tuesday, April 7, 2026 – Wednesday April 8 – (MedPage Today) — Novo Nordisk said its semaglutide (Wegovy) pill outperformed recently approved orforglipron (Foundayo) in weight loss and tolerability in an indirect comparison using clinical trial data, and the company launched multi-month…

Tuesday, April 7, 2026 – Wednesday April 8 – Plus, news about Vertex and Halozyme, Werewolf, and Regeneron:

Novo Nordisk launches high-dose Wegovy in the US: The 7.2 mg injectable form of the GLP-1 agonist is now available in the US to treat obesity …

Tuesday, April 7, 2026 – Wednesday April 8 – Insurers score Medicare Advantage wins, the obesity drug race continues, and other biotech news from The Readout

Tuesday, April 7, 2026 – Wednesday April 8 – The FDA has approved a new once-daily GLP-1 pill for weight loss. Image Credit: Healthline/Photo by Eli Lilly

Federal regulators have approved the GLP-1 tablet Foundayo for use in weight management.

Experts say having another weight loss medication in pill form could help people stick to a weight management regimen.

Monday, April 6, 2026 – MONDAY, April 6, 2026 — Ixekizumab plus tirzepatide (IXE+TZP) shows significant benefits for outcomes in psoriatic arthritis (PsA) versus IXE alone in adults with overweight or obesity, according to a study presented at the annual meeting of the…

Monday, April 6, 2026 – Tuesday, April 7 – Combat muscle loss with this 7-move routine.

Monday, April 6, 2026 – Tuesday, April 7 – Ixekizumab plus tirzepatide (IXE+TZP) shows significant benefits for outcomes in psoriatic arthritis (PsA) versus IXE alone in adults with overweight or obesity, according to a study presented at the annual meeting of the American Academy of Dermatology, held from March 27 to 31 in Denver.

Monday, April 6, 2026 – Tuesday, April 7 – Originally developed to treat diabetes, a class of drugs known as glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are now stepping into the spotlight as weight loss drugs. A recent umbrella review draws attention to safety concerns regarding the use of this GLP medication, alongside a mix of potential benefits.

Saturday, April 4, 2026 – Sunday, April 5 – (MedPage Today) — TTHealthWatch is a weekly podcast from Texas Tech. In it, Elizabeth Tracey, director of electronic media for Johns Hopkins Medicine in Baltimore, and Rick Lange, MD, president of Texas Tech Health El Paso, look at the top medical…

Thursday, April 2, 2026 – Friday, April 3 – PLAINSBORO, NJ and BAGSVÆRD, Denmark, April 2, 2026 /PRNewswire/ — Novo Nordisk will present the ORION study at the upcoming Obesity Medicine Association’s annual conference in San Diego showing that Wegovy® (semaglutide) tablets 25…

Thursday, April 2, 2026 – Friday, April 3 – Their effectiveness also depends on what else you do when you take them.

Thursday, April 2, 2026 – THURSDAY, April 2, 2026 — A popular weight loss drug may soon be more affordable for some people.
Danish pharmaceutical company Novo Nordisk has launched a subscription program for its obesity treatment Wegovy, offering lower and more…

Thursday, April 2, 2026 – THURSDAY, April 2, 2026 — Glucagon-like peptide-1 (GLP-1) receptor agonist (RA) use is associated with delayed wound healing in patients undergoing abdominal panniculectomy, according to a study published in the April issue of Plastic and…

Thursday, April 2, 2026 – Friday, April 3 – A day after Eli Lilly gained FDA approval for its obesity pill Foundayo, Novo Nordisk is fighting back with an analysis that it says shows the superiority of its own oral drug.

…

Thursday, April 2, 2026 – Friday, April 3 – (MedPage Today) — As a primary care physician and obesity board-certified specialist, I believe that GLP-1s are one of the best medical interventions of all time, right up there with vaccines, antibiotics, blood thinners, and statins. They really…

Thursday, April 2, 2026 – Friday, April 3 – Potential import tariffs on drugs, Foundayo is here-o, and other biotech news from The Readout

Wednesday, April 1, 2026 – Thursday, April 2 – Eli Lilly and Co. anticipates shipping newly approved Foundayo (orforglipron) within the next week, as the drug becomes the second oral weight-loss glucagon-like peptide-1 (GLP-1) receptor agonist to enter the U.S. market following December’s approval of Novo Nordisk A/S’ Wegovy (semaglutide) pill.

Wednesday, April 1, 2026 – Thursday, April 2 – Wegovy (semaglutide) has passed the notoriously strict cost-effectiveness scrutiny of the U.K. health technology assessment body and will now be reimbursed for the prevention of further serious cardiovascular events in people who have had a heart attack or stroke, or are diagnosed with peripheral arterial disease.

Wednesday, April 1, 2026 – Thursday, April 2 – Physical activity is crucial when you’re taking this medication.

Wednesday, April 1, 2026 – Thursday, April 2 – (MedPage Today) — The FDA has approved a second oral GLP-1 receptor agonist for weight loss in adults with obesity or overweight and weight-related comorbidities.
A once-daily tablet, orforglipron (Foundayo) is indicated in conjunction with a…

Wednesday, April 1, 2026 – Thursday, April 2 – Eli Lilly’s once-daily Foundayo is the second obesity pill to receive FDA approval. It will compete with Novo Nordisk’s pill version of Wegovy.

Wednesday, April 1, 2026 – WEDNESDAY, April 1, 2026 — For adults with type 2 diabetes (T2D) who were not achieving glycemic control while receiving a stable dose of dulaglutide, switching to tirzepatide is associated with improvement in patient-reported outcomes (PROs)…

Wednesday, April 1, 2026 – Thursday, April 2 – Now Eli Lilly has an obesity pill, too.

On Wednesday, the FDA approved orforglipron, the agency announced. It will be sold as Foundayo, and Lilly has previously said it plans to …

Wednesday, April 1, 2026 – Thursday, April 2 – Microdosing GLP-1 drugs is trending on social media and supported by some doctors, but experts warn the practice lacks a standard protocol and may undermine weight-loss results.

Wednesday, April 1, 2026 – Thursday, April 2 – Now Eli Lilly has an obesity pill, too.

On Wednesday, the FDA approved orforglipron, the agency announced. It will be sold as Foundayo, and Lilly said it plans to sell a …

Wednesday, April 1, 2026 – Thursday, April 2 – While peptides are currently the dominant approach to GLP-1 agonism, Ambrosia Biosciences is pursuing a small-molecule approach.